Medtronic Announces First Live Experience of Sugar.IQ with Watson for People Living with Diabetes
September 27 2016 - 9:00AM
Sugar.IQ with Watson Cognitive App
to Preview at Health 2.0 Conference
DUBLIN and SANTA CLARA, Calif. -
Sept. 27, 2016 - Medtronic plc (NYSE:MDT), the global leader in
medical technology, today announced that Sugar.IQ with Watson, the
first-of-its-kind cognitive app that helps detect important
patterns and trends for people with diabetes, is now in live use
for the first time. With app development now completed, the first
users are participating in real-world testing of the final release
candidate. Developed with IBM Watson Health, the Sugar.IQ app will
be demonstrated at the 10th Annual
Health 2.0 Fall Conference in Santa Clara, Calif.
The Sugar.IQ app uses real-time continuous glucose
monitoring (CGM) and insulin information from Medtronic pumps and
glucose sensors. It leverages IBM cognitive computing power,
combined with Medtronic's expertise in diabetes, to find hidden
patterns in diabetes data and will offer real-time and personalized
insights so that people with diabetes can spend less time worrying
about their data and have more freedom to simply enjoy life. The
app will provide individualized guidance in understanding and
helping to manage elements of daily diabetes decisions by creating
a single platform that brings together relevant data and provides
context and insights.
"We have made great progress in development of the
Sugar.IQ app since unveiling the first research concepts at CES
2016," said Annette Brüls, president, Diabetes Service and
Solutions at Medtronic. "Through our collaboration with IBM Watson
Health, Medtronic will arm people with diabetes with a unique
solution that could uncover previously unknown patterns while
serving as a personal assistant that offers meaningful information
when it matters to help transform diabetes care for greater freedom
and better health."
In the coming days, Medtronic and IBM will offer a
limited launch of the application to 100 MiniMed® Connect mobile
accessory users, who will have the opportunity to explore the
design and usability of the Sugar.IQ app, and provide valuable
feedback on their experience ahead of the apps broader roll-out
later this year.
"The Medtronic-IBM partnership has advanced
rapidly and today's debut of the final release candidate of the
Medtronic Sugar.IQ app with Watson is proof positive of that
progress," said Deborah DiSanzo, general manager for IBM Watson
Health. "We look forward to learning from the pilot how
Watson-derived insights can potentially help people living with
diabetes better manage their condition."
The final release candidate of the Sugar.IQ app
will also be demonstrated on Health 2.0's Main Stage during a live
on-stage panel presentation titled "Data Drives Decisions &
Discovery: Intelligence for a New Era" on Sept. 27, 2016 at 10:45
a.m.
The Sugar.IQ app will help answer key questions
that people with diabetes have about their current health status,
about where their health is trending and what actions they can take
to better manage their diabetes in the future as part of their
disease-management plan with their provider.
- Insights - As the Sugar.IQ
app uncovers behaviors associated with glucose patterns,
personalized messages will be delivered in real-time to help people
with diabetes understand how specific actions and habits affect
their glucose levels.
- Glycemic Assist - People
with diabetes can ask the Sugar.IQ app to follow specific food- or
therapy-related actions and events. By following items, Sugar.IQ
will help discover the impact these items have on their personal
glucose levels.
- Food logging - The Sugar.IQ
app will quickly and easily track food in a diary to deliver
meal-related insights that illustrate how specific foods impact an
individual's glucose levels.
Once commercially available, the Sugar.IQ app will
be offered to people with diabetes who use Medtronic's continuous
glucose monitoring sensors and insulin pumps and will be a
companion app for those using the MiniMed Connect mobile
accessory.
About the Diabetes Group at
Medtronic (www.medtronicdiabetes.com)
Medtronic is working together with the global community to change
the way people manage diabetes. The company aims to transform
diabetes care by expanding access, integrating care and improving
outcomes, so people living with diabetes can enjoy greater freedom
and better health.
About Medtronic
Medtronic plc (www.medtronic.com), headquartered in Dublin,
Ireland, is among the world's largest medical technology, services
and solutions companies - alleviating pain, restoring health and
extending life for millions of people around the world. Medtronic
employs more than 88,000 people worldwide, serving physicians,
hospitals and patients in approximately 160 countries. The company
is focused on collaborating with stakeholders around the world to
take healthcare Further, Together.
Any forward-looking statements
are subject to risks and uncertainties such as those described in
Medtronic's periodic reports on file with the Securities and
Exchange Commission. Actual results may differ materially from
anticipated results.
-end-
Contacts:
Pamela Reese
Public Relations
+1-818-576-3398
Ryan Weispfenning
Investor Relations
+1-763-505-4626
This
announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Medtronic plc via Globenewswire
Medtronic (NYSE:MDT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Medtronic (NYSE:MDT)
Historical Stock Chart
From Sep 2023 to Sep 2024